Uniting Wealth Partners LLC Takes Position in Intuitive Surgical, Inc. $ISRG

Uniting Wealth Partners LLC bought a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the third quarter, HoldingsChannel reports. The institutional investor bought 1,519 shares of the medical equipment provider’s stock, valued at approximately $679,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC grew its position in shares of Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after purchasing an additional 731 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Intuitive Surgical by 3.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after purchasing an additional 34 shares during the period. Harbour Investments Inc. grew its holdings in Intuitive Surgical by 95.5% in the 2nd quarter. Harbour Investments Inc. now owns 2,976 shares of the medical equipment provider’s stock valued at $1,617,000 after buying an additional 1,454 shares in the last quarter. Mutual Advisors LLC increased its position in Intuitive Surgical by 5.7% during the 2nd quarter. Mutual Advisors LLC now owns 1,605 shares of the medical equipment provider’s stock worth $796,000 after buying an additional 86 shares during the period. Finally, Nordea Investment Management AB lifted its holdings in shares of Intuitive Surgical by 6.2% during the second quarter. Nordea Investment Management AB now owns 43,921 shares of the medical equipment provider’s stock worth $23,632,000 after buying an additional 2,549 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Gary S. Guthart sold 24,500 shares of the business’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $530.10, for a total transaction of $12,987,450.00. Following the completion of the transaction, the director owned 3,694 shares of the company’s stock, valued at approximately $1,958,189.40. The trade was a 86.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Fredrik Widman sold 133 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $494.96, for a total transaction of $65,829.68. Following the completion of the sale, the vice president owned 660 shares in the company, valued at approximately $326,673.60. The trade was a 16.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 56,189 shares of company stock worth $30,785,441. Insiders own 0.70% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several research reports. Royal Bank Of Canada upped their price target on shares of Intuitive Surgical from $625.00 to $650.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Zacks Research downgraded shares of Intuitive Surgical from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Evercore cut their price target on Intuitive Surgical from $580.00 to $550.00 and set an “in-line” rating for the company in a research note on Friday, January 23rd. Rothschild & Co Redburn raised their price objective on Intuitive Surgical from $610.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Finally, TD Cowen raised Intuitive Surgical to a “strong-buy” rating in a report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $617.23.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $485.84 on Friday. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $609.08. The stock has a market capitalization of $172.54 billion, a price-to-earnings ratio of 61.58, a price-to-earnings-growth ratio of 3.76 and a beta of 1.65. The company’s 50 day simple moving average is $541.62 and its 200 day simple moving average is $510.34.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share for the quarter, topping the consensus estimate of $2.27 by $0.26. Intuitive Surgical had a return on equity of 15.06% and a net margin of 28.38%.The firm had revenue of $2.87 billion during the quarter, compared to analysts’ expectations of $2.72 billion. During the same period in the prior year, the company earned $2.21 earnings per share. The company’s quarterly revenue was up 18.8% on a year-over-year basis. As a group, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.